Dr. Andrew N. Hoofnagle's lab at the University of Washington focuses on improving blood tests for patients with type 1 diabetes. Their research aims to make these tests more reliable and easier to reproduce in different labs, which is crucial for personalized medicine. By using advanced technologies like mass spectrometry, the lab seeks to better understand diabetes and improve the management of the disease through more accurate biomarkers.

Dr. Marcelo Dietrich's lab at Yale University studies how the early interactions between mothers and infants shape brain development and social behavior. They focus on understanding specific neuron types that influence these interactions and the impacts of early life adversity, like childhood maltreatment, on long-term mental health. By investigating these neural systems in mice, the lab aims to uncover insights that could enhance developmental outcomes and help address social and psychological disorders.

Lars Dietrich's lab at Columbia University studies the opportunistic bacterium Pseudomonas aeruginosa, known for causing serious infections, particularly in vulnerable populations. They focus on understanding how these bacteria survive and thrive in challenging environments, such as during infections, by examining unique structures like R-bodies that help protect the bacteria and contribute to their virulence. The research aims to uncover the mechanisms behind these survival tactics to identify new treatment strategies against bacterial infections.

Scott Dixon's lab at Stanford University focuses on understanding how specific cellular processes can lead to the death of small cell lung cancer (SCLC) cells. By studying the unique metabolism of these cancer cells, particularly how they handle cysteine—a vital amino acid—the lab aims to identify new therapeutic strategies to improve outcomes for SCLC patients. Researchers will explore the differences in cell death mechanisms based on the metabolic state of the cancer cells to develop targeted enzyme therapies.

Dr. Jean-Pierre Etchegaray's lab at Rutgers focuses on understanding how DNA modifications affect intestinal health. Specifically, they study how a family of enzymes called TETs can modify DNA in intestinal cells, impacting their response to environmental stressors like gut bacteria and infections. Their research aims to uncover mechanisms that maintain intestinal cell function and protect against diseases such as colitis.

Dr. Irene E Chiolo's lab focuses on understanding how cells repair DNA double-strand breaks (DSBs) that occur due to various environmental factors and normal cellular processes. Specifically, the lab studies repair mechanisms in a specialized part of the genome called heterochromatin, which is notoriously difficult to work with due to its complex structure. By investigating the movement and organization of repair sites, the lab aims to uncover the molecular machinery that protects the genome from instability, providing insights into cancer development and potential treatments.

Dylan Dodd's lab at Stanford University focuses on harnessing gut microbiota to develop probiotics that can help treat genetic metabolic disorders, like Phenylketonuria (PKU). By understanding how gut bacteria influence human metabolism, the lab aims to create innovative therapies that utilize these beneficial microbes to control metabolic pathways. Their long-term goal is to lay the groundwork for new approaches to treat various inborn errors of metabolism.

Dr. Kimberly L Dodge-Kafka's lab at the University of Connecticut focuses on understanding how specific calcium signaling pathways contribute to heart conditions, particularly cardiac hypertrophy. The lab is investigating how calcium microdomains affect signaling in heart cells and aims to develop new treatments for heart disease by targeting these pathways. Their research emphasizes the role of certain protein complexes in regulating calcium signals that can lead to heart remodeling and failure.

Daniel A Dombeck's lab at Northwestern University focuses on understanding how neurons adapt and change in response to various stimuli, which is crucial for learning and memory. They use advanced imaging techniques to observe how changes in brain signals occur in real-time, helping to clarify how our brains function during behaviors like spatial navigation. Their work has important implications for treating conditions related to brain plasticity, such as addiction and chronic pain.

Dr. Paul D. Drew's lab focuses on understanding how fetal alcohol exposure affects brain development, particularly through the impact on oligodendrocyte-lineage cells that are essential for myelination in the central nervous system. The research aims to uncover the mechanisms of neurological deficits associated with Fetal Alcohol Spectrum Disorders (FASD), with hopes of finding therapeutic approaches for prevention and treatment. By utilizing rodent models, the lab explores the interactions between oligodendrocyte cells and neurons and seeks potential strategies to enhance myelination in affected brains.

Dr. Nicole Dubois' research lab focuses on understanding how the heart's basic building blocks, known as sarcomeres, are formed during development and how RNA-binding proteins like DDX3X play crucial roles in heart function and disease. By studying the mechanisms that lead to congenital heart defects and cardiomyopathies, the lab aims to uncover new therapeutic targets for heart diseases. They utilize cutting-edge technologies to explore both the structural and functional aspects of heart development.

Stephen A. Duncan's lab focuses on discovering new drugs that can lower cholesterol production in the liver, which is crucial for addressing high cholesterol issues in patients. By using a type of liver cell derived from human stem cells, the lab investigates the effects of several small molecules that inhibit a specific enzyme called carboxylesterase 1. These findings could lead to treatments for conditions like familial hypercholesterolemia and fatty liver disease without the side effects associated with current cholesterol medications.

Dr. Dana Duren's lab at the University of Missouri-Columbia focuses on improving treatment strategies for craniofacial disorders by utilizing advanced 3D imaging technology. The lab develops new models of craniofacial growth that better reflect real-world conditions based on a diverse dataset of children and young adults. Their work aims to enhance clinical practice by providing evidence-based standards for timing treatments, leading to better outcomes for patients.

Dr. Joyita Dutta's research lab focuses on using wearable technology to discover biomarkers for early detection of Alzheimer's disease. The lab is investigating how changes in sleep patterns, monitored by devices like smartwatches and EEG headbands, can signal the risk of developing Alzheimer's in older adults. By combining data from these wearables with genetic information, the research aims to improve early diagnosis and ultimately contribute to better management of the disease.

Dr. Brian Dynlacht's lab at NYU School of Medicine focuses on understanding how primary cilia, tiny structures on the surface of cells, are assembled and disassembled. These cilia are crucial for sensing signals from the environment and play important roles in cell growth and division. The lab studies specific proteins that help configure cilia and other cellular structures, which can have implications in developmental defects and cancer. By uncovering the connections between protein functions and cellular processes, the lab aims to advance knowledge in cell biology and potential disease mechanisms.

Dr. Ruth Anne Eatock's lab at the University of Chicago studies how the inner ear processes head movements to maintain balance and stable vision. The research focuses on different types of hair cells in the vestibular system, examining how they send signals to the brain during motion. By understanding the mechanisms behind sensory signal integration and how different nerve fibers encode head motion, this lab contributes to our understanding of balance and spatial orientation.

Dr. Alexander Bukreyev's lab focuses on understanding how the immune system improperly responds to Ebola virus infection. The research aims to identify the molecular mechanisms that cause both excessive inflammation and immune paralysis in affected individuals. By studying these processes, the lab hopes to contribute to the development of effective treatments for Ebola virus and similar viral infections.

Dr. Mo Reza Ebrahimkhani's lab focuses on creating advanced in vitro human organoids that mimic the structure and function of real human tissues. The research aims to improve the engineering of these organoids by using synthetic and systems biology methods, which can enhance their development and robustness. By utilizing genetically engineered clones and computational models, the lab seeks to address challenges in organoid maturity and diversity, ultimately contributing to advancements in regenerative medicine and reducing reliance on animal models.

Dr. Takeshi Egawa's lab at Washington University focuses on understanding how CD8 T cells, a vital part of the immune system, make decisions about their fate when they respond to infections or vaccinations. By investigating the roles of specific signaling pathways and transcription factors, the lab aims to uncover the mechanisms that lead to T cell differentiation, memory formation, and their potential for use in immunotherapy against cancers. This research is essential for developing improved treatments that harness the body's immune response to fight chronic infections and cancer.

Dr. Mikala Egeblad's lab at Johns Hopkins University studies how chronic psychological stress influences cancer metastasis. The research focuses on understanding the biological pathways between the brain and the body that contribute to the spread of cancer, particularly through the activation of stress-related hormones and immune responses. By using mouse models, the lab aims to uncover mechanisms that could eventually lead to better prevention and treatment strategies for metastatic cancers.